Source comparison
Cartalax vs Epithalon — Peptide Comparison | Real Peptides
Bioregulatory peptides aren't interchangeable—the amino acid sequence determines everything. Cartalax (Ala-Glu-Asp) operates through tissue-specific organ peptide pathways in cartilage and bone, while Epithalon (Ala-Glu-Asp-Gly) activates pineal gland mechanis
This comparison does not assign a generated winner or score.
- Bioregulatory peptides aren't interchangeable—the amino acid sequence determines everything. Cartalax (Ala-Glu-Asp) operates through tissue-specific organ peptide pathways in cartilage and bone, while Epithalon (Ala-Glu-Asp-Gly) activates pineal gland mechanisms linked to circadian biology and telomerase expression. The structural difference is a single glycine residue, but the functional difference spans organ systems, half-life kinetics, and primary endpoints. Researchers working with joint degeneration models don't substitute one for the other—the targeting mechanisms are fundamentally incompatible.
- Our team has synthesized both compounds under identical small-batch protocols for over six years. The confusion arises because both belong to the Khavinson peptide family developed at the St. Petersburg Institute of Bioregulation and Gerontology, but their applications diverge completely once you examine receptor affinity and tissue distribution data.
- What is the difference between Cartalax and Epithalon in research applications?
- Cartalax is a tripeptide bioregulator studied for cartilage matrix synthesis and skeletal tissue repair, with rapid plasma clearance (half-life ~3 hours). Epithalon is a tetrapeptide researched for pineal gland modulation, telomerase activation, and circadian rhythm normalization, demonstrating longer tissue retention. The two peptides target different organ systems through distinct receptor pathways and cannot substitute for one another in study design.
- Yes, both compounds originated from the same Russian research lineage under Vladimir Khavinson's cytogenic regulation theory—but citing common ancestry misses the point entirely. Cartalax demonstrates selective uptake in chondrocytes and osteoblasts via organ-specific peptide recognition sequences. Epithalon bypasses the blood-brain barrier to reach pineal tissue, where it influences melatonin synthesis and telomere maintenance pathways. This article covers the structural biochemistry of Cartalax vs Epithalon, comparative pharmacokinetics and tissue distribution patterns, and the exact experimental contexts where one peptide performs functions the other cannot replicate.